Free Trial
NASDAQ:QSI

Quantum-Si Q2 2025 Earnings Report

Quantum-Si logo
$1.87 +0.06 (+3.31%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$1.87 0.00 (0.00%)
As of 07/9/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Quantum-Si EPS Results

Actual EPS
N/A
Consensus EPS
-$0.16
Beat/Miss
N/A
One Year Ago EPS
N/A

Quantum-Si Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.28 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Quantum-Si Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 6, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Quantum-Si Earnings Headlines

Financial Survey: Quantum-Si (NASDAQ:QSI) versus Diodes (NASDAQ:DIOD)
Trump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?
Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that you don't want to take with your retirement savings.
See More Quantum-Si Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quantum-Si? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quantum-Si and other key companies, straight to your email.

About Quantum-Si

Quantum-Si (NASDAQ:QSI), Inc. (NASDAQ: QSI) is a life sciences technology company focused on the development of next-generation protein sequencing and characterization platforms. Founded in 2017 and headquartered in Guilford, Connecticut, the company has built a proprietary platform designed to enable researchers to sequence proteins at the single-molecule level. By combining microfluidics, advanced quantum sensor technologies and machine learning algorithms, Quantum-Si seeks to advance the field of proteomics with enhanced sensitivity and throughput compared to traditional mass spectrometry methods.

The core offering from Quantum-Si is the Infinity™ platform, which integrates sample preparation, fluidics control and a high-resolution quantum semiconductor detector. This system is intended to provide detailed protein identity and abundance data, empowering drug discovery, biomarker research and basic biological studies. Quantum-Si’s technology aims to tackle challenges such as low-abundance protein detection, post-translational modification mapping and complex sample analysis, supporting a broad range of applications in pharmaceutical R&D and clinical proteomics.

Quantum-Si collaborates with academic institutions, biotechnology firms and pharmaceutical companies worldwide, with customers and partners across North America, Europe and the Asia-Pacific region. The company has established strategic alliances for co-development projects, pilot studies and technology evaluations, positioning its platform as a complementary tool for existing proteomic workflows. Quantum-Si also offers reagent kits, consumables and technical support services to accelerate adoption and integration of its technology in research laboratories.

Leadership at Quantum-Si includes President and Chief Executive Officer Steve Rasmussen, who brings extensive experience in genomics and life science instrumentation, and Chief Financial Officer Mark Soudie. Under their guidance, the company has transitioned from early development into commercial readiness, expanding its engineering, operations and customer success teams. Quantum-Si continues to invest in R&D, manufacturing scale-up and global customer engagement to drive the next wave of proteomic innovation.

View Quantum-Si Profile

More Earnings Resources from MarketBeat